CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0107 (clinicaltrials.gov NCT No: NCT01456689)
Title:A multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in patients with relapsed and/or refractory multiple myeloma
Principal Investigator:Sheeba K. Thomas
Treatment Agent:LGH447
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of LGH447 that can be given to patients with MM. The safety of the drug will
also be tested.

LGH447 is designed to block proteins that are thought to cause cancer cells to
grow.

This is the first study using LGH447 in humans.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:LGH447
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults